In the NewsGenetic Engineering & Biotechnology News (GEN): Tolerogenic Therapies Retrain the Immune System In the News / lsc-webmaster
In the NewsBioSpace: After 10 Years of Hard Work, COUR Treads Into Pharma’s Myasthenia Gravis Territory In the News / lsc-webmaster
In the NewsManaged Healthcare Executive: Nanoparticle Therapy has Potential to Reprogram the Immune System in Type 1 Diabetes In the News / lsc-webmaster
In the NewsBioWorld: Cour’s CNP-103 gains IND clearance for type 1 diabetes In the News / lsc-webmaster
In the NewsLiver Disease News: Cour’s CNP-104 granted FDA orphan drug status for treating PBC In the News / lsc-webmaster
In the NewsHealio: Cour Pharmaceuticals snags orphan drug designation for CNP-104 for the treatment of PBC In the News / lsc-webmaster
In the NewsHCPLive: FDA Grants Orphan Drug Designation to CNP-104 for Primary Biliary Cholangitis In the News / lsc-webmaster
In the NewsEndpoints News: Roche teams up with Chicago autoimmune biotech COUR Pharmaceuticals In the News / lsc-webmaster
In the NewsFirstWord Pharma: Roche onboards COUR to develop autoimmune nanoparticle therapy In the News / lsc-webmaster
In the NewsFierce Biotech: Cour links up with Roche’s Genentech in autoimmune deal that could exceed $940M In the News / lsc-webmaster
